Moderna (MRNA) Tax Provisions (2018 - 2026)
Moderna (MRNA) posted quarterly Tax Provisions of $15.0 million for Q2 2026, up 114.29% year-over-year from $7.0 million in Q2 2025, and up 66.67% on a QoQ basis from $9.0 million in Q1 2026.
Moderna (MRNA) Tax Provisions (2018 - 2026) Analysis & Trends
Moderna has reported Tax Provisions for 9 years, with the latest figure at $15.0 million in Q2 2026.
- Tax Provisions for Q2 2026 came in at $15.0 million, up 114.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $64.0 million (up 252.38% YoY), and the FY2025 annual result was $54.0 million, up 217.39% from the prior year.
- Tax Provisions grew to $15.0 million in Q2 2026, from $9.0 million in the prior quarter.
- Over five years, Tax Provisions peaked at $1.7 billion in Q3 2023 and troughed at -$384.0 million in Q1 2023.
- A 5-year average of $118.6 million and a median of $10.0 million in 2024 frame the typical range for Tax Provisions.
- The widest annual swing landed in 2022, when Tax Provisions soared 1366.67%; it then plunged 233.21% in 2023.
- A 5-year view of Tax Provisions shows it stood at $190.0 million in 2022, then tumbled by 177.37% to -$147.0 million in 2023, then surged by 56.46% to -$64.0 million in 2024, then surged by 142.19% to $27.0 million in 2025, then tumbled by 44.44% to $15.0 million in 2026.
- Per Business Quant data, the three most recent Tax Provisions figures were $15.0 million in Q2 2026, $9.0 million in Q1 2026, and $27.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 15.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.00 Mn |
| Mar 31, 2026 | 9.00 Mn |
| Dec 31, 2025 | 27.00 Mn |
| Sep 30, 2025 | 13.00 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | -64.00 Mn |
| Sep 30, 2024 | 8.00 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | -147.00 Mn |
| Sep 30, 2023 | 1.67 Bn |
| Jun 30, 2023 | -369.00 Mn |
| Mar 31, 2023 | -384.00 Mn |
| Dec 31, 2022 | 190.00 Mn |
| Sep 30, 2022 | 174.00 Mn |
| Jun 30, 2022 | 277.00 Mn |
| Mar 31, 2022 | 572.00 Mn |
| Dec 31, 2021 | 542.00 Mn |
| Sep 30, 2021 | 219.00 Mn |
| Jun 30, 2021 | 283.00 Mn |